Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will

neutrophil count
cold agglutinin
fludarabine
indolent lymphoma
cytopenia
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

This is a Phase I, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of a novel BTK inhibitor, ICP-022. During this study, dose escalation

neutrophil count
chronic lymphocytic leukemia
lymphocytic leukemia
cancer
renal function tests
  • 7 views
  • 28 Jan, 2021
  • 8 locations
A Study of ICP-022 in Patients With R/R DLBCL

It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There

b-cell lymphoma
btk inhibitor
  • 0 views
  • 24 Jan, 2021
  • 6 locations
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor

neutrophil count
measurable disease
refractory mantle cell lymphoma
flow cytometry
cancer
  • 1 views
  • 24 Jan, 2021
  • 1 location
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK

neutrophil count
chronic lymphocytic leukemia
g-csf
gilbert's syndrome
monoclonal protein
  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study of BNC105P Combined With Ibrutinib

A Phase I Trial of BNC105P in combination with BTK inhibitor ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia(CLL). This study proposes that ibrutinib will have far

chronic lymphocytic leukemia
neutrophil count
flow cytometry
anemia
bendamustine
  • 62 views
  • 08 Feb, 2021
  • 1 location
Ibrutinib Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

employ three target therapy drugs in sequencing phases. It will start with a BTK inhibitor as induction, later an anti-CD20 will be used for consolidation and it will end with a BH3 analog as maintenance

chronic lymphocytic leukemia
tyrosine
monoclonal protein
ibrutinib
chronic lymphocytic leukemia refractory
  • 0 views
  • 23 Jan, 2021
  • 2 locations
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

is considered experimental. Experimental means that it is still being tested to see if it is safe and effective. Ibrutinib is a new drug known as a 'Bruton's Tyrosine Kinase (BTK) inhibitor

measurable disease
tyrosine
lymphocytic leukemia
chronic lymphocytic leukemia
cancer
  • 88 views
  • 25 Jan, 2021
  • 1 location
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib. Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for patients with mantle cell lymphoma who have received at least one prior therapy. Ixazomib is …

measurable disease
tyrosine
refractory mantle cell lymphoma
neutrophil count
cancer
  • 129 views
  • 26 Jan, 2021
  • 16 locations
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has …

neutrophil count
chronic lymphocytic leukemia
cancer
anemia
renal function tests
  • 20 views
  • 24 Jan, 2021
  • 9 locations